In AL amyloidosis, abnormal plasma cells in the bone marrow produce misfolded proteins that clump together clump together ...

The cereblon E3 ligase modulator, given in combination with Amgen's Kyprolis (carfilzomib) and dexamethasone (Kd) as ...

At this year’s ASCO Annual Meeting, Pfizer had three major Phase 3 oral presentations: CROWN, TALAPRO-3, and BREAKWATER, each paired with simultaneous publications in leading medical journals.

Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows ...

Revolution Medicines' pan-RAS (on) inhibitor daraxonrasib has delivered a big result in pancreatic cancer, with a doubling in overall survival compared to chemotherapy in the highly anticipated ...

The FDA has started a priority review of Sanofi's Gaucher disease therapy venglustat, a potentially first-in-class therapy, ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Sudden unexpected death is a terrifying consequence faced by people living with uncontrolled tonic-clonic seizures (TCSs), so ...

The Singapore Court of Appeal has retained an injunction against KBP Bio and its founder, Dr Huang Zhenhua, and ruled that a ...

Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with ...

AI has implications across the value chain in oncology, including in the diagnostics space, where agentic AI is making it easier to access and understand genomic data – an advance with applications in ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, can achieve a functional cure in 19% of patients, ...